Stock Scorecard
Stock Summary for Boston Scientific Corp (BSX) - $103.17 as of 8/18/2025 12:20:51 PM EST
Total Score
8 out of 30
Safety Score
60 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for BSX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for BSX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for BSX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for BSX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for BSX (60 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 6 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 5 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 4 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 2 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for BSX
Financial Details for BSX
Company Overview |
|
|---|---|
| Ticker | BSX |
| Company Name | Boston Scientific Corp |
| Country | USA |
| Description | Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. |
| Sector Name | LIFE SCIENCES |
| Industry Name | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 10/22/2025 |
Stock Price History |
|
| Last Day Price | 103.17 |
| Price 4 Years Ago | 42.48 |
| Last Day Price Updated | 8/18/2025 12:20:51 PM EST |
| Last Day Volume | 5,342,558 |
| Average Daily Volume | 7,117,102 |
| 52-Week High | 108.94 |
| 52-Week Low | 77.71 |
| Last Price to 52 Week Low | 32.76% |
Valuation Measures |
|
| Trailing PE | 61.99 |
| Industry PE | 40.37 |
| Sector PE | 59.06 |
| 5-Year Average PE | 37.58 |
| Free Cash Flow Ratio | 286.58 |
| Industry Free Cash Flow Ratio | 40.94 |
| Sector Free Cash Flow Ratio | 30.26 |
| Current Ratio Most Recent Quarter | 1.37 |
| Total Cash Per Share | 0.36 |
| Book Value Per Share Most Recent Quarter | 15.14 |
| Price to Book Ratio | 6.88 |
| Industry Price to Book Ratio | 4.88 |
| Sector Price to Book Ratio | 26.93 |
| Price to Sales Ratio Twelve Trailing Months | 8.34 |
| Industry Price to Sales Ratio Twelve Trailing Months | 4.13 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.21 |
| Analyst Buy Ratings | 24 |
| Analyst Strong Buy Ratings | 6 |
Share Statistics |
|
| Total Shares Outstanding | 1,481,750,000 |
| Market Capitalization | 152,872,147,500 |
| Institutional Ownership | 94.03% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 1.94% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 140.90% |
| Annual Earnings Growth | 16.38% |
| Reported EPS 12 Trailing Months | 1.68 |
| Reported EPS Past Year | 1.50 |
| Reported EPS Prior Year | 2.51 |
| Net Income Twelve Trailing Months | 2,502,000,000 |
| Net Income Past Year | 1,854,000,000 |
| Net Income Prior Year | 1,593,000,000 |
| Quarterly Revenue Growth YOY | 22.80% |
| 5-Year Revenue Growth | 9.30% |
| Operating Margin Twelve Trailing Months | 18.60% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 534,000,000 |
| Total Cash Past Year | 414,000,000 |
| Total Cash Prior Year | 865,000,000 |
| Net Cash Position Most Recent Quarter | -10,447,000,000 |
| Net Cash Position Past Year | -8,428,000,000 |
| Long Term Debt Past Year | 8,842,000,000 |
| Long Term Debt Prior Year | 8,566,000,000 |
| Total Debt Most Recent Quarter | 10,981,000,000 |
| Equity to Debt Ratio Past Year | 0.71 |
| Equity to Debt Ratio Most Recent Quarter | 0.67 |
| Total Stockholder Equity Past Year | 21,770,000,000 |
| Total Stockholder Equity Prior Year | 19,282,000,000 |
| Total Stockholder Equity Most Recent Quarter | 22,418,000,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 3,698,000,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 2.50 |
| Free Cash Flow Past Year | 2,645,000,000 |
| Free Cash Flow Prior Year | 1,703,000,000 |
Options |
|
| Put/Call Ratio | 0.51 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.36 |
| MACD Signal | 0.09 |
| 20-Day Bollinger Lower Band | 93.46 |
| 20-Day Bollinger Middle Band | 102.18 |
| 20-Day Bollinger Upper Band | 110.90 |
| Beta | 0.66 |
| RSI | 42.54 |
| 50-Day SMA | 96.05 |
| 150-Day SMA | 69.96 |
| 200-Day SMA | 62.83 |
System |
|
| Modified | 8/15/2025 7:30:04 PM EST |